7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis by Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Baumgartner SW, Lin S-L

Connect to this object online.

Rilonacept (IL-1 TRAP) for treatment of colchicine resistant familial mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial by Reiff AO, Pashinian N, Weisman MH, Barron KS, Park G, Huang B, Giannini EH, Spalding SJ, Hashkes PJ, Samuels J, Wright D, Kastner DL, Lovell DJ

Connect to this object online.

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept by Ruperto N, Lovell DJ, Li T, Paz E, Horneff G, Huppertz HI, Deslandre CJ, Minden K, Punaro M, Nunez AF, Sigal L, Block A, Covucci A, Martini A, Giannini EH

Connect to this object online.

Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients by Ruperto N, Lovell DJ, Li T, Quartier P, Chavez J, Huemer C, Kivitz A, Blanco F, Foeldvari I, Hofer M, Sigal L, Block A, Covucci A, Martini A, Giannini EH

Connect to this object online.

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis by Wouters C, McIlraith MJ, Ilowite N, Chalom E, Jones OY, Koné-Paut I, Higgins G, Gamir M, Reiff A, Lovell DJ, Ruperto N, Liu S, Kupper H, Giannini EH, Martini A

Connect to this object online.

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a... by McCann L, Ozdogan H, Rutkowska-Sak L, Ferrandiz MA, Wulffraat NM, Brik R, Kallinich T, Erguven M, Berkun Y, Constantin T, Quartier P, Horneff G, Brunner H, Ruperto N, Lheritier K, Preiss R, Tseng L, Martini A, Lovell DJ

Connect to this object online.

2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatme... by Ruperto N, Lovell DJ, Cuttica R, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH

Connect to this object online.